Calico (California Life Company)
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
Calico employs mainstream, peer-recognized aging researchers and has a well-documented corporate and funding history, but its research outputs are largely undisclosed publicly, and its most consequential public partnership, with AbbVie, ended in 2025 after a high-profile clinical trial failure.
Reference only. Not medical advice.
Calico is a biotechnology company majority owned by Alphabet Inc. and based in South San Francisco, California, dedicated to researching the fundamental biology of aging and developing therapies aimed at extending healthy human lifespan. Unlike most biotech startups, it was established with the explicit backing and balance sheet of one of the world's largest technology companies, giving it a long investment horizon rare in the industry. Its scientific staff, roughly a few hundred people, has included prominent aging researchers such as National Academy of Sciences members Cynthia Kenyon, known for extending nematode lifespan through insulin signaling mutations, and Daniel Gottschling, alongside geneticist David Botstein, giving the company significant credibility within academic aging science despite its low public profile. From 2014 through 2025, Calico's primary vehicle for translating research into drugs was its alliance with AbbVie, under which both companies committed up to 1.5 billion dollars, later increased by another billion, to jointly discover and develop treatments for neurodegenerative disease and cancer linked to aging. That partnership ended in November 2025 after AbbVie's jointly developed ALS drug candidate, fosigotifator, failed in Phase II or III trials, resulting in layoffs of roughly 100 Calico-affiliated scientists and chemists as AbbVie shifted its own pipeline priorities toward biologics. Calico has also collaborated with academic partners including the Broad Institute, the Buck Institute for Research on Aging, and QB3, and previously with AncestryDNA on a large scale genetic study of longevity and family history, though that collaboration ended. The company has drawn some criticism from outside researchers and journalists for its unusual secrecy about ongoing projects and for publishing comparatively little relative to its scale and funding, a posture Calico has defended by arguing that aging biology requires a decade or more of sustained, low-noise research before results are ready to share. Within the longevity field, Calico is generally viewed as a serious, well-resourced, scientifically mainstream effort, distinguished by its roster of established academic researchers, even as its slow, closed-door publication record makes independent evaluation of its progress difficult.
Calico is a biotechnology company majority owned by Alphabet Inc.
What people get wrong
Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
How we got here
Announced by Google on September 18, 2013, and founded by former Google Ventures CEO Bill Maris, with Genentech's former chairman and CEO Arthur D. Levinson installed as founder and CEO. Google co-founder Larry Page described its mission in that year's founders letter as tackling 'health, well-being, and longevity.' Calico became a stand-alone subsidiary of Alphabet Inc. when Google reorganized under that holding company in 2015, and in September 2014 it entered a research and development alliance with pharmaceutical company AbbVie worth up to 1.5 billion dollars, later expanded, that ran until AbbVie exited the partnership and reduced Calico's staff in November 2025 following disappointing late-stage trial results.
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Calico (California Life Company). A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- What can go wrong. We have not written the risk line for this one. Read the safety section below rather than treating its absence as reassurance.
- Where we land. We have not taken a position on this yet.
- What people take it for. We have not catalogued the claims made for it.